CY1110344T1 - Φαρμακευτικο σκευασμα περιεχον ενα αντισωμα εναντιον του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egf) - Google Patents

Φαρμακευτικο σκευασμα περιεχον ενα αντισωμα εναντιον του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egf)

Info

Publication number
CY1110344T1
CY1110344T1 CY20101100415T CY101100415T CY1110344T1 CY 1110344 T1 CY1110344 T1 CY 1110344T1 CY 20101100415 T CY20101100415 T CY 20101100415T CY 101100415 T CY101100415 T CY 101100415T CY 1110344 T1 CY1110344 T1 CY 1110344T1
Authority
CY
Cyprus
Prior art keywords
receptor
growth factor
antibody against
egf
container containing
Prior art date
Application number
CY20101100415T
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Robert Müller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110344(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1110344T1 publication Critical patent/CY1110344T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Η εφεύρεση αφορά ένα υδατικό φαρμακευτικό σκεύασμα περιέχον ένα αντίσωμα εναντίον του υποδοχέα του ενδοθηλιακού αυξητικού παράγοντα (υποδοχέας EGF). Το σκεύασμα εμφανίζει μία αυξημένη σταθερότητα αποθήκευσης ακόμα και σε υψηλές θερμοκρασίες και μπορεί να χρησιμοποιηθεί για την θεραπεία καρκίνων.
CY20101100415T 2003-11-26 2010-05-13 Φαρμακευτικο σκευασμα περιεχον ενα αντισωμα εναντιον του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egf) CY1110344T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10355251A DE10355251A1 (de) 2003-11-26 2003-11-26 Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
EP04820387A EP1687031B1 (de) 2003-11-26 2004-10-26 Pharmazeutische zubereitung enthaltend einen antikörper gegen den rezeptor für einen epidermalen wachstumsfaktor (egf-rezeptor)

Publications (1)

Publication Number Publication Date
CY1110344T1 true CY1110344T1 (el) 2015-01-14

Family

ID=34609304

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100415T CY1110344T1 (el) 2003-11-26 2010-05-13 Φαρμακευτικο σκευασμα περιεχον ενα αντισωμα εναντιον του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egf)

Country Status (31)

Country Link
US (2) US20050175611A1 (el)
EP (1) EP1687031B1 (el)
JP (1) JP2007512266A (el)
KR (1) KR20060110305A (el)
CN (1) CN1886158B (el)
AR (1) AR047949A1 (el)
AT (1) ATE457740T1 (el)
AU (1) AU2004298728B2 (el)
BR (1) BRPI0416986A (el)
CA (1) CA2547060A1 (el)
CO (1) CO5690620A2 (el)
CY (1) CY1110344T1 (el)
DE (2) DE10355251A1 (el)
DK (1) DK1687031T3 (el)
EC (1) ECSP066662A (el)
ES (1) ES2339671T3 (el)
HK (1) HK1095534A1 (el)
IL (1) IL175727A0 (el)
MX (1) MXPA06005901A (el)
MY (1) MY145214A (el)
NZ (1) NZ548129A (el)
PE (1) PE20050586A1 (el)
PL (1) PL1687031T3 (el)
PT (1) PT1687031E (el)
RU (1) RU2381036C2 (el)
SG (1) SG150550A1 (el)
SI (1) SI1687031T1 (el)
TW (1) TWI322693B (el)
UA (1) UA90460C2 (el)
WO (1) WO2005058365A1 (el)
ZA (1) ZA200605219B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
SI2548577T1 (sl) 2005-12-29 2017-05-31 Janssen Biotech, Inc. Človeška protitelesa proti il-23, sestavki, postopki in uporabe
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
MEP39508A (en) * 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090181027A1 (en) * 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
CN101797383A (zh) * 2009-02-05 2010-08-11 哈药集团生物工程有限公司 一种单克隆抗体的水针制剂
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
RU2012131099A (ru) * 2009-12-29 2014-02-10 Ф. Хоффманн-Ля Рош Аг Препарат антитела
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012269240B2 (en) * 2011-06-16 2016-01-21 Dpx Holdings B.V. Single unit chromatography antibody purification
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
KR102205512B1 (ko) 2012-11-13 2021-01-20 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3020947B1 (fr) * 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
AU2016308111A1 (en) 2015-08-18 2018-03-01 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
US20210322554A1 (en) * 2018-09-10 2021-10-21 Dow Global Technologies Llc A composition comprising a protein and a polyalkoxy fatty acyl surfactant
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
EP3883607A4 (en) 2018-11-20 2022-08-17 Janssen Biotech, Inc. SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
JP2022513693A (ja) * 2018-11-29 2022-02-09 ハーバー・バイオメド・セラピューティクス・リミテッド 抗ｐｄ－ｌ１抗体製剤
AU2020216978A1 (en) 2019-01-31 2021-09-09 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2022230390A1 (ja) * 2021-04-27 2022-11-03 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の保存方法、放射性医薬組成物の調製または保存方法、放射性医薬組成物の中間体組成物、および、医薬製剤
CN115300623A (zh) * 2021-05-08 2022-11-08 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497500C2 (ru) * 1995-07-27 2013-11-10 Джинентех, Инк Стабильная изотоническая лиофилизированная протеиновая композиция
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
NZ526720A (en) * 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
JP2006514954A (ja) * 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物

Also Published As

Publication number Publication date
TWI322693B (en) 2010-04-01
CN1886158B (zh) 2011-09-07
DK1687031T3 (da) 2010-05-31
CN1886158A (zh) 2006-12-27
DE502004010783D1 (de) 2010-04-01
US20050175611A1 (en) 2005-08-11
BRPI0416986A (pt) 2007-02-06
EP1687031B1 (de) 2010-02-17
AU2004298728B2 (en) 2010-09-16
JP2007512266A (ja) 2007-05-17
CA2547060A1 (en) 2005-06-30
ES2339671T3 (es) 2010-05-24
KR20060110305A (ko) 2006-10-24
DE10355251A1 (de) 2005-06-23
PE20050586A1 (es) 2005-08-15
AR047949A1 (es) 2006-03-15
CO5690620A2 (es) 2006-10-31
RU2381036C2 (ru) 2010-02-10
TW200531702A (en) 2005-10-01
SG150550A1 (en) 2009-03-30
PL1687031T3 (pl) 2010-06-30
MXPA06005901A (es) 2006-06-27
US20110177068A1 (en) 2011-07-21
MY145214A (en) 2012-01-13
AU2004298728A1 (en) 2005-06-30
HK1095534A1 (en) 2007-05-11
IL175727A0 (en) 2006-09-05
ZA200605219B (en) 2007-04-25
RU2006122638A (ru) 2008-01-10
NZ548129A (en) 2010-09-30
SI1687031T1 (sl) 2010-04-30
UA90460C2 (ru) 2010-05-11
PT1687031E (pt) 2010-05-21
ATE457740T1 (de) 2010-03-15
WO2005058365A1 (de) 2005-06-30
ECSP066662A (es) 2006-10-25
EP1687031A1 (de) 2006-08-09

Similar Documents

Publication Publication Date Title
CY1110344T1 (el) Φαρμακευτικο σκευασμα περιεχον ενα αντισωμα εναντιον του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egf)
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
CY1108361T1 (el) ΣΤΑΘΕΡΟ ΣΚΕΥΑΣΜΑ ΠΟΥ ΠΕΡΙΕΧΕΙ TNFR-Fc ΚΑΙ ΑΡΓΙΝΙΝΗ
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CO5720212A1 (es) Composicion de anticuerpo her2
AR054474A1 (es) Formulacion de anticuerpos estables
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
DE60134251D1 (de) Verwendung von glp-2-peptiden
ATE433961T1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
CY1111095T1 (el) Υδατοδεις συνθεσεις που περιεχουν μετρονιδαζολη
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
EA200801430A1 (ru) Производные триазола
ATE531529T1 (de) Wertdokument, herstellung und prüfung von wertdokumenten
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
DE60226852D1 (de) Lentivirale verpackungskonstrukte
CY1112992T1 (el) Μεσο καλλιεργειας χωρις ορο για την παρασκευη ανασυνδυασμενων γοναδοτροπινων
ATE292136T1 (de) Seltenerdmetallverbindungen und deren mischungen
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet